Trial Profile
A prospective multicenter study of ripasudil effects for secondary glaucoma
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 01 Feb 2020
Price :
$35
*
At a glance
- Drugs Ripasudil (Primary)
- Indications Glaucoma
- Focus Therapeutic Use
- 24 Jul 2018 Status changed from recruiting to active, no longer recruiting.
- 30 Oct 2015 Status changed from not yet recruiting to recruiting, as reported by University Hospital Medical Information Network - Japan record.
- 27 Oct 2015 Planned initiation date changed from 17 Aug 2018 to 30 Oct 2015, as reported by University Hospital Medical Information Network - Japan record.